Ugo Boccadifuoco, Ivan Lerner, Auria Godard, Luc Darnige, Laure Joseph, Wassim El Nemer, Geoffrey Cheminet, Jean-Benoit Arlet
Although circulating nucleated red blood cells (cNRBCs) have previously been detected in patients with sickle cell disease (SCD), their prevalence and clinical significance during steady-state disease have not been established. We retrospectively analyzed 270 adults with an SS or Sβ0-thalassemia genotype. cNRBCs were counted during steady-state disease. Patients were classified as high cNRBC+ (> 3 per 100 white blood cells (WBCs)), low cNRBC+ (1-3 per 100 WBCs), or cNRBC- (no cNRBCs). cNRBC+ and cNRBC- patients were compared with regard to clinical and laboratory data and in vitro erythroid differentiation from peripheral blood CD34+ cells. cNRBCs were detected in 65.6% of the patients and encompassed all terminal erythroid stages. High cNRBC+ patients were more likely to be receiving hydroxyurea (p = 0.024). cNRBC+ patients exhibited a lower median [IQR] hemoglobin level (8.8 [7.8-10] and 8.4 [7.4-9.4] in the high and low cNRBC+ groups, respectively vs. 9.3 [8.3-9.9] g/dL in the cNRBC- group; p = 0.024). The cNRBC+ percentage was correlated negatively with the reticulocyte and WBC counts and positively with the mean corpuscular volume and the ferritin level. Clinically, a trend toward a greater likelihood of acute chest syndrome was observed in cNRBC+ patients. High cNRBC+ patients' cells exhibited accelerated erythroid differentiation in vitro, suggestive of dyserythropoiesis. cNRBCs constitute a common, easily measurable marker of a distinct hematological phenotype in adult patients with SCD: more severe anemia and signs of dyserythropoiesis. Prospective studies are needed to determine the value of the cNRBC percentage for predicting disease severity and guiding the treatment of dyserythropoiesis.